Published in Mol Ther Nucleic Acids on September 10, 2013
Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev (2013) 1.12
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01
Targeting autophagy in breast cancer. World J Clin Oncol (2014) 0.99
Targeting autophagy in cancer management - strategies and developments. Cancer Manag Res (2015) 0.89
FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget (2016) 0.84
Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: sequential delivery of doxorubicin and Bcl-2 siRNA. Sci Rep (2014) 0.84
PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nat Commun (2016) 0.79
Microtubule-associated protein 4 is an important regulator of cell invasion/migration and a potential therapeutic target in esophageal squamous cell carcinoma. Oncogene (2016) 0.79
Curcumin induces apoptosis of upper aerodigestive tract cancer cells by targeting multiple pathways. PLoS One (2015) 0.76
si-RNA-Mediated Silencing of ADRBK1 Gene Attenuates Breast Cancer Cell Proliferation. Cancer Biother Radiopharm (2014) 0.75
Apogossypolone induces apoptosis and autophagy in nasopharyngeal carcinoma cells in an in vitro and in vivo study. Oncol Lett (2017) 0.75
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell (2005) 21.01
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol (2008) 20.89
Autophagy as a regulated pathway of cellular degradation. Science (2000) 17.27
Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol (2004) 8.85
Potential therapeutic applications of autophagy. Nat Rev Drug Discov (2007) 8.56
The role of autophagy in cancer development and response to therapy. Nat Rev Cancer (2005) 8.18
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov (2004) 4.73
Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release (2006) 3.85
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Bcl-2 family proteins and cancer. Oncogene (2008) 3.42
BCL-2 gene family and the regulation of programmed cell death. Cancer Res (1999) 2.89
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy (2010) 2.62
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J (2003) 2.11
Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene (2002) 2.03
Autophagic cell death: Loch Ness monster or endangered species? Autophagy (2011) 1.82
Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun (2002) 1.75
Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy (2008) 1.71
The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res (2010) 1.54
Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am (1995) 1.54
Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res (2008) 1.51
Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J (2002) 1.37
Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med (2010) 1.36
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med (2010) 1.35
Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene (1997) 1.27
bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer (2000) 1.22
B1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms. Apoptosis (2008) 1.22
Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. Mol Pharmacol (2006) 1.15
Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther (2007) 1.11
Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res (2007) 1.10
Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol (2009) 1.08
Targeting the Bcl-2. Curr Opin Oncol (2009) 1.08
Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One (2010) 1.06
Crosstalk between Bak/Bax and mTOR signaling regulates radiation-induced autophagy. Autophagy (2007) 1.05
PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy (2007) 1.04
alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+/calmodulin-dependent protein kinase IV. J Cell Biochem (2005) 1.04
Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state. Int J Cancer (2002) 1.02
BCL-2 promotes migration and invasiveness of human glioma cells. FEBS Lett (1998) 1.00
Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res (2008) 0.98
Downregulation of autophagy by Bcl-2 promotes MCF7 breast cancer cell growth independent of its inhibition of apoptosis. Cell Death Differ (2010) 0.94
Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors. Hum Pathol (2011) 0.93
Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther (2010) 0.92
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol (2003) 0.91
Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol (2003) 0.87
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy (2010) 2.62
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res (2011) 1.84
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer (2005) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res (2009) 1.73
Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy (2008) 1.71
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther (2010) 1.71
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res (2007) 1.68
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res (2007) 1.66
Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun (2008) 1.66
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res (2005) 1.63
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol (2012) 1.61
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61
Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol (2005) 1.61
Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun (2010) 1.61
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell (2013) 1.60
Glucose as a prognostic factor in ovarian carcinoma. Cancer (2009) 1.59
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res (2006) 1.59
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem (2010) 1.58
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther (2006) 1.57
Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res (2002) 1.57
Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol (2008) 1.57
EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer (2007) 1.57
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol (2008) 1.56
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res (2008) 1.55
Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem (2007) 1.54